Comprehensive Insights About 50+ Companies and 60+ Pipeline Drugs

Home Comprehensive Insights About 50+ Companies and 60+ Pipeline Drugs
Written by Doug Hampton

DUBLIN, June 1, 2023 /PRNewswire/ — The “Advanced Renal Cell Carcinoma – Pipeline Insight, 2023” drug pipelines has been added to’s offering.

This report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.

Advanced Renal Cell Carcinoma Emerging Drugs Chapters

This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Renal Cell Carcinoma

There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme.

Advanced Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.

Key Questions Answered

  • How many companies are developing Advanced Renal Cell Carcinoma drugs?
  • How many Advanced Renal Cell Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Renal Cell Carcinoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Renal Cell Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Merck Sharp & Dohme
  • Chia Tai Tianqing Pharmaceutical
  • Hoffmann-La Roche
  • CoImmune
  • Infinity Pharmaceuticals
  • NiKang Therapeutics
  • Molecure S.A.
  • Daiichi Sankyo
  • Janux Therapeutics
  • MedImmune
  • Eli Lilly and Company
  • Jiangsu HengRui Medicine Co., Ltd.
  • Allogene Therapeutics
  • Chongqing Precision Biotech Co., Ltd
  • Pfizer
  • Exelixis
  • BeiGene
  • Xencor

Key Products

  • TQB2450
  • Belzutifan
  • Atezolizumab
  • CMN-001
  • IPI-549
  • NKT2152
  • OATD-02
  • DS-6000a
  • JANX008
  • MEDI5752
  • Abemaciclib
  • SHR-1210
  • ALLO-316
  • CD70 CAR-T cells
  • Selenomethionine
  • XL092
  • BGB-A445
  • XmAb819

For more information about this drug pipelines report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets

Leave a Comment